logo

CAPR

Capricor·NASDAQ
--
--(--)
--
--(--)

CAPR fundamentals

Capricor (CAPR) released its earnings on Mar 12, 2026: revenue was 0 (YoY -100.00%), missed estimates; EPS was -0.62 (YoY -287.50%), missed estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.62
-287.50%
Report date
Mar 12, 2026
CAPR Earnings Call Summary for Q4,2025
  • FDA Milestone Achievement: BLA for Deramiocel accepted with PDUFA date of August 22, 2026, after successful HOPE-3 data submission.
  • Clinical Success: HOPE-3 trial shows 91% disease progression slowing in cardiac function and statistically significant improvement in upper limb function and fibrosis reduction.
  • Manufacturing Scale-Up: $318M cash position supports 250-patient/year initial capacity, with expansion to 2,500/year by late 2027.
  • Commercial Focus: Rapid patient access strategy includes market access, reimbursement, and physician education post-approval.
  • Pipeline Momentum: StealthX platform advancing toward IND, with potential for exosome-based therapies in multiple indications.
EPS
Revenue

Revenue & Expenses

Key Indicators

Capricor (CAPR) key financial stats and ratios, covering profitability, financial health, and leverage.
Capricor (CAPR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Capricor (CAPR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Capricor (CAPR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Capricor (CAPR) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Capricor (CAPR) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield